Skip to content
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

LivaNova PLC LIVN

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.4B
▲ 10.7% YoY
$-242.5M
▼ 483.5% YoY
$173.3M
▲ 27.5% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

LivaNova PLC designs, develops, manufactures, markets and sells medical products, therapies and services. As of December 31, 2025, LivaNova had approximately 3,300 employees worldwide, representing more than 80 nationalities and located in 34 countries. LivaNova manufactures a majority of its products in facilities located in the U.S., Italy, Germany, Australia and Brazil. It is organized into two reportable segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment designs, develops, manufactures, markets and sells cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems and cannulae, and provides related services. The Neuromodulation segment designs, develops, manufactures, markets and sells devices, including the VNS Therapy System, that deliver neuromodulation therapy for treating DRE and DTD. LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England.

Written from the business description in LivaNova PLC's annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.4B
Revenue, FY2025 · full 12-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.4 · Net income -0.2
0.5B1.0B-0.1B-0.3B
20132017202020232025
Compound annual growth
+10.8%
+8.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−17 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 14.4% · Net -17.5%
10%20%30%-10%-20%-30%
201320192025
ROE
FY2025 · ROE -19.2%
10%20%-10%-20%
201320192025
Three returns, three denominators.

Each USD of equity lost 19 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 173.3
100M200M-50M-100M
201320192025
Net buybacks $M Dividends $M
FY2020 · Dividends · · Net buybacks 0.0
25.0M50.0M
2013201420162017201820192020

Total assetsUSD 2.6B
EquityUSD 1.2B
CashUSD 635.6M
Gross debtUSD 376.1M
Net debtUSD -259.5M
Current ratio1.36×

The company holds more cash than debt.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LIVN, 12-year financial record
Metric 202520242023202220212020201920182017201620142013
Revenue $B1.41.31.21.01.00.91.11.11.01.00.30.3
Operating income $B0.20.1−0.1−0.1−0.0−0.3−0.2−0.20.10.00.10.1
EBITDA $B0.20.2−0.0−0.10.0−0.2−0.1−0.20.10.10.10.1
Income tax $B0.00.0−0.10.00.0−0.0−0.0−0.10.00.00.00.0
Net income $B−0.20.10.0−0.1−0.1−0.3−0.2−0.2−0.0−0.10.10.1
Free cash flow $B0.20.10.00.00.1−0.1−0.10.10.10.10.10.0
EPS, diluted $−4.451.160.32−1.61−2.68−7.18−3.26−3.91−0.52−1.282.172.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %−19.24.91.4−6.9−11.3−28.0−11.0−11.4−1.4−3.721.621.2
Shares out B0.050.050.050.050.050.050.050.050.0548.030.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 2 divergences in 57 reconciliationsAUDITED

Reconciled in 10 of the 12 fiscal years we could check. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 14 checks were skipped: the balance sheet is not tagged before 2014. Six checks were skipped: EPS is not tagged before 2013. Six checks were skipped: revenue is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures2 divergent
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image